Patents by Inventor Mark L. Heiman

Mark L. Heiman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190374570
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 12, 2019
    Inventors: Mark L. HEIMAN, Dean P. STULL, Justin W. PENO
  • Patent number: 10441602
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 15, 2019
    Assignee: MicroBiome Therapeutics, LLC
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
  • Publication number: 20170080015
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 23, 2017
    Inventors: Mark L. HEIMAN, Dean P. STULL, Justin W. PENO
  • Publication number: 20170065554
    Abstract: The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, IBD, and gastrointestinal dysbiosis.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 9, 2017
    Inventors: Mark L. HEIMAN, Stephen M. BOUE
  • Patent number: 9463169
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: October 11, 2016
    Assignee: MicroBiome Therapeutics, LLC
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
  • Patent number: 9040101
    Abstract: Compositions and methods for treating diabetes are presented herein. In particular, the present disclosure teaches compositions and methods for treating diabetes utilizing a gastrointestinal microbiome modulating composition.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: May 26, 2015
    Assignee: MicroBiome Therapeutics LLC.
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W Peno
  • Publication number: 20150118330
    Abstract: Compositions and methods for treating diabetes are presented herein. In particular, the present disclosure reaches compositions and methods for treating diabetes utilizing a gastrointestinal microbiome modulating composition.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Applicant: MICROBIOME THERAPEUTICS LLC
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
  • Publication number: 20140294997
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Application
    Filed: August 17, 2012
    Publication date: October 2, 2014
    Applicant: NuMe Health Inc.
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
  • Publication number: 20140275233
    Abstract: The present invention provides, among other things, compositions and methods of manufacturing edible soy pod fiber comprising glyceollins. In some embodiments, methods of treating overweight, obesity, prediabetes, diabetes, or gastrointestinal dysbiosis in a subject are provided comprising orally administering a composition or food product comprising edible soy pod fiber comprising glyceollins.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventor: Mark L. Heiman
  • Patent number: 5965521
    Abstract: This invention provides a method for optimizing the administration of leptin receptor ligands to a mammal in need of such treatment. More specifically, this invention provides an improved method of delivering leptin receptor ligands to a mammal in need of such treatment comprising pulsatile or peak delivery of leptin receptor ligands to treat obesity and related conditions, including hyperglucocorticoidinemia, fertility or delayed puberty, and/or growth hormone deficiencies.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: October 12, 1999
    Assignee: Eli Lilly Company
    Inventors: Thomas W. Stephens, Mark L. Heiman, Jose F. Caro
  • Patent number: 4904642
    Abstract: An octapeptide of the formula: ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl), or R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H; A.sub.3 is CH.sub.2 -A.sub.6 (where A.sub.6 is pentafluorophenyl, naphthyl, pyridyl, or phenyl); A.sub.4 is o- m- or p-substituted X-Phe (where X is a halogen, H, NO.sub.2, OH, NH.sub.2, or C.sub.1-3 alkyl), pentafluoro-Phe, or .beta.-Nal; A.sub.5 is Thr, Ser, Phe, Val, .alpha.-aminobutyric acid, or Ile, provided that when A.sub.3 is phenyl, A.sub.1 is H, and A.sub.2 is H, A.sub.5 cannot be Val; and A.sub.7 is Thr, Trp, or .beta.-Nal; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 17, 1989
    Date of Patent: February 27, 1990
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, William A. Murphy, Mark L. Heiman
  • Patent number: 4853371
    Abstract: An octapeptide of the formula: ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl, R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H; A.sub.3 is CH.sub.2 -A.sub.6 (where A.sub.6 is pentafluorophenyl, naphthyl, pyridyl, or phenyl); A.sub.4 is o- m- or p-substituted X-Phe (where X is a halogen, H, NO.sub.2, OH, NH.sub.2, or C.sub.1-3 alkyl), pentafluoro-Phe, or .alpha.-Nal; A.sub.5 is Thr, Ser, Phe, Val, .alpha.-aminobutyric acid, or Ile, provided that when A.sub.3 is phenyl, A.sub.1 is H, and A.sub.2 is H, A.sub.5 cannot be Val; and A.sub.7 is Thr, Trp, or .beta.-Nal; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 22, 1988
    Date of Patent: August 1, 1989
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, William A. Murphy, Mark L. Heiman